


Safinamide mesylate

Cat. No.:	HY-70057A
CAS No.:	202825-46-5
Molecular Formula:	C ₁₈ H ₂₃ FN ₂ O ₅ S
Molecular Weight:	398.45
Target:	Monoamine Oxidase
Pathway:	Neuronal Signaling
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (627.43 mM; Need ultrasonic)
 H₂O : ≥ 20 mg/mL (50.19 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.5097 mL	12.5486 mL	25.0972 mL
	5 mM	0.5019 mL	2.5097 mL	5.0195 mL
	10 mM	0.2510 mL	1.2549 mL	2.5097 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (5.22 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (5.22 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.22 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Safinamide (FCE 26743; EMD 1195686) mesylate is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.098 μM) over MAO-A (IC₅₀=580 nM)^[1]. Safinamide mesylate also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC₅₀=8 μM) than at resting (IC₅₀=262 μM) potentials. Safinamide mesylate has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke et.al^{[2][3]}.

IC₅₀ & Target

MAO-B

MAO-A

	98 nM (IC ₅₀)	580 nM (IC ₅₀)
In Vitro	<p>Safinamide mesylate (1-300 μM) reduces the amplitude of the peak sodium currents in a concentration-dependent manner. When currents are stimulated to a V_{test} of +10 mV from a V_h of -110 mV, the IC₅₀ value was 262 μM. When the holding potential is depolarized to -53 mV, the inhibitory effect of Safinamide mesylate with a lower IC₅₀ value (8 μM) in rat cortical neurons^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	
In Vivo	<p>Safinamide mesylate (intraperitoneal injection; 90 mg/kg; once daily; 14 days) treatment prior to MCAO significantly ameliorates MCAO-caused cerebral infarction volume, neurological deficit, disruption of the brain-blood barrier (BBB), and impairs expression of tight junction protein occludin and ZO-1 in mice^[3].</p> <p>Safinamide mesylate (intraperitoneal injection; 5 mg/kg, 15 mg/kg and 30 mg/kg) dose dependently inhibits the veratridine-induced GABA release and Glu release in vivo. At the dose 30 mg/kg, Safinamide mesylate prevents the effect of veratridine both on Glu (treatment F_{1,8}=1.31; time×treatment interaction F_{8,64}=2.4) and GABA (treatment F_{1,8}=4.04; time F_{8,64}=3.76, time×treatment interaction F_{8,64}=2.83) release.</p> <p>Safinamide mesylate causes a slight, albeit not significant, reduction of veratridine-stimulated Glu release at 0.5 mg/kg and full inhibition at 5 and 15 mg/kg in rat^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	

CUSTOMER VALIDATION

- Ecotoxicol Environ Saf. 2023 Aug 7;262:115284.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Leonetti F, et al. Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. *J Med Chem*, 2007, 50(20), 4909-4916.
- [2]. C Caccia, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. *Neurology*. 2006 Oct 10;67(7 Suppl 2):S18-23.
- [3]. Michele Morari, et al. Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia. *J Pharmacol Exp Ther*. 2018 Feb;364(2):198-206.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA